LEPU BIO-B(02157) reports significant growth in net profit, expected to be no less than 200 million yuan, turning losses into profits year-on-year.

LEPU BIO-B (02157) announced that it is expected that the net profit attributable to shareholders for the year ending December 31, 2025 (reporting period) will be no less than RMB 200 million, an increase of no less than RMB 611 million compared to the loss of approximately RMB 411 million for the year ending December 31, 2024. The expected turnaround to profit and significant increase in net profit attributable to shareholders are mainly attributed to the following factors: The company achieved strong revenue growth through domestic commercialization and licensing transactions: Significant revenue growth mainly came from Puyouheng (Pertuzumab injection) and Meihouheng (Bevacizumab injection), with Meihouheng generating initial revenue after obtaining approval from the National Medical Products Administration in October 2025; With the continuous expansion of licensing transactions, including the external licensing of MRG007 and CTM012 and CTM013 (two preclinical TCE assets of the company), the company's profitability continues to grow; and For the year ending December 31, 2025, the company recognized a one-time gain from the reclassification of an investment from an associate company to an investment measured at fair value. This change was due to the company no longer having significant influence over the investee company. Such gains are non-recurring and non-operational in nature.